Download Publication list ANDRI RAUCH, MD

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
13.09.2012
Publication list ANDRI RAUCH, MD
A) Original articles
Bold: First or corresponding author
Nr.
1
2
3
4
5
6
7
8
9
10
11
A Rauch, M Rickenbach, R Weber, B Hirschel, P Tarr, H Bucher, P Vernazza, E
Bernasconi, AS Zinkernagel, J Evison, H Furrer. Unsafe sex and increasing
incidence of Hepatitis C Virus infection among HIV infected men who have
sex with men: The Swiss HIV Cohort Study. Clinical Infectious Diseases
2005;41:395- 402.
A Rauch, M Egger, J Reichen, HJ Furrer. Chronic hepatitis C in HIV-infected
patients: Low eligibility and applicability of therapy with pegylated
interferon alfa plus ribavirin. Journal of AIDS 2005;38:238-40. (original
research letter)
A Rauch, D Nolan, A Martin, E McKinnon, C Almeida, S Mallal. Prospective
genetic screening decreases the incidence of abacavir hypersensitivity
reactions in the Western Australian HIV Cohort. Clinical Infectious Diseases
2006;43:99-102.
S Gaudieri*, A Rauch*, L Park, E Freitas, S Herrmann, G Jeffrey, W Cheng, K
Pfafferott, Vanessa Naidoo, Russell Chapman, Manuel Battegay, Rainer
Weber, Amalio Telenti, Hansjakob Furrer, Ian James, Michaela Lucas, Simon
A Mallal. Evidence of viral adaptation to HLA Class I-restricted immune
pressure in chronic Hepatitis C virus infection. Journal of Virology 2006;
80:11094-104. *shared first authors
M Lucas, A Ulsenheimer, K Pfafferot, MH Heeg, S Gaudieri, N Grüner, A
Rauch, J Tilman Gerlach, MC Jung, R Zachoval, G Pape, W Schraut, T
Santantonio, H Nitschko, M Obermeier, R Phillips, T Scriba, N Semmo, C Day,
J Weber, S Fidler, R Thimme, A Heberstroh, TF Baumert, P Klenerman, H
Diepolder. Tracking virus-specific CD4+ T cells during and after acute
hepatitis C virus infection. PLoS ONE 2007; 7:e649.
A Rauch, Silvana Gaudieri, John Evison, David Nolan, Matthias Cavassini,
Rainer Weber, Ian James, Hansjakob Furrer. Low current and nadir CD4 Tcell counts are associated with higher Hepatitis C viral loads in the Swiss HIV
Cohort Study. Antiviral Therapy, 2008;13:455-60. *corresponding author
A Rauch*, D Nolan, H Furrer, E McKinnon, M John, S Mallal, S Gaudieri, H
Günthard, P Schmid, M Battegay, B Hirschel, A Telenti, I James. HLA-Bw4
Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after
Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2008;
46:1921-5. *corresponding author
S Colombo*, A Rauch*, M Rotger, J Fellay, R Martinez, C Fux, C Thurnheer, H
Günthard, D Goldstein, H Furrer, A Telenti. The HCP5 Single-Nucleotide
Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity
Reaction to Abacavir. Journal of Infectious Diseseas, 2008;198:864-7 .
*shared first authors
A Rauch*, D Nolan, C Turnheer, C Fux, M Cavassini, J Chave, M Opravil, E
Phillips, S Mallal, H Furrer. Refining Abacavir Hypersensitivity Diagnoses
using Structured Clinical Asessment and Genetic Testing in the Swiss HIV
Cohort Study. Antiviral Therapy, 2008;13:1019-28. *corresponding author
G Clifford, M Rickenbach, J Polesel, L Dal Maso, I Steffen, B Ledergerber, A
Rauch, N Probst-Hensch, C Bouchardy, F Levi, S Franceschi. Influence of HIV
related immunodeficiency on the risk of hepatocellular carcinoma. AIDS,
2008;22:2135-41.
C Fux, A Rauch, M Simcock, H Bucher, B Hirschel, M Opravil, P Vernazza, M
Cavassini, E Bernasconi, L Elzi, H Furrer. Tenofovir use is associated with an
IF 2011
Ranking
9.154
0,986
4,425
0,857
9.154
0,986
5.44
0,844
4.092
0.867
3.161
0,741
9.154
0,986
6.41
0,971
3.161
0,741
6,245
0.957
3.161
0,741
12
13
14
15
16
17
18
19
20
21
22
23
24
increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
Antiviral Therapy, 2008;13:1077-82.
S Gaudieri, A Rauch, K Pfafferott, E Barnes, W Cheng, G McCaughan, N
Shackel, G Jeffrey, L Mollison, R Baker, H Furrer, H Günthard, E. Freitas, I.
Humphreys, P Klenerman, S Mallal, I James, S Roberts, D Nolan, M Lucas.
Hepatitis C Virus Drug Resistance and Immune-Driven Adaptations:
Relevance to New Antiviral Therapy. Hepatology, 2009 Apr;49(4):1069-82.
C Combescure, N Vallier, B Ledergerber, M Cavassini, H Furrer, A Rauch, M
Battegay, E Bernasconi, P Vernazza, B Hirschel. How Reliable Is An
Undetectable Viral Load? HIV-Medicine, 2009 Sep;10(8):470-6.
A Kesselring, F Wit, C Sabin, J Lundgren, M Gill, J Gatell, A. Rauch, J.
Montaner, F de Wolf, P. Reiss, A. Mocroft. Risk factors for treatment-limiting
toxicities in patients starting nevirapine-containing antiretroviral therapy.
AIDS, 2009 24;23:1689-99.
M Tschochner, A Chopra, TM Maiden, IF Ahmad, I James, HJ Furrer, HF
Günthard, S Mallal, A Rauch, M John. Effects of HIV-1 immune selection on
susceptibility to integrase inhibitor resistance, Antiviral Therapy,
2009;14(7):953-64.
T Ferry, B Hirschel, T Dang, P Meylan, C Delhumeau, A Rauch, R Weber, L
Elzi, E Bernasconi, P Schmid, A Calmy, the Swiss HIV Cohort Study. Infrequent
Replication of Parvovirus B19 and Erythrovirus Genotypes 2 and 3 among
HIV-Infected Patients with Chronic Anemia. Clinical Infect Diseases, 2010 Jan
1;50(1):115-8.
M May, R Wood, L Myer, P Taffé, A Rauch, M Battegay, M. Egger. CD4+ T Cell
Count Decreases by Ethnicity among Untreated Patients with HIV Infection
in South Africa and Switzerland. Journal of Infectious Diseases. 2009
1;200(11):1729-35.
A Rauch, I James, K Pfafferott, D Nolan, P Klenerman, W Cheng, L Mollison, G
McCaughan, N Shackel, GP Jeffrey, R Baker, E Freitas, I Humphreys, H Furrer,
H Günthard, B Hirschel, S Mallal, M. John, M. Lucas, E. Barnes, S. Gaudieri.
Divergent Adaptation of Hepatitis C Virus Genotypes 1 and 3 to Human
Leukocyte Antigen–Restricted Immune Pressure. Hepatology,
2009;50(4):1017-29.
A Rauch*, Z Kutalik, P Descombes, T Cai, J Di Iulio J, T Mueller, M Bochud, M
Battegay, E Bernasconi, E Borovicka, S Colombo, A Cerny JF Dufour, H Furrer,
H Günthard, M Heim, B Hirschel, R Malinverni, D Moradpour, B Müllhaupt, A
Witteck, J Beckmann, T Berg, S Bergmann, F Negro, A Telenti, PY
Bochud.Genetic variation in IL28B is associated with chronic hepatitis C and
treatment failure: a genome-wide association study. Gastroenterology. 2010
Apr;138(4):1338-45. *corresponding author
Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK,
Vernazza P, Bernasconi E, Mueller NJ, Weber R. Incidence and risk factors for
chronic elevation of alanine aminotransferase levels in HIV-infected persons
without hepatitis b or c virus co-infectionClin Infect Dis. 2010 Feb
15;50(4):502-11.
Casado C, Colombo S, Rauch A, Martínez R, Günthard HF, Garcia S, Rodríguez
C, Del Romero J, Telenti A, López-Galíndez C. Host and viral genetic
correlates of clinical definitions of HIV-1 disease progression. PLoS One.
2010 Jun 11;5(6):e11079.
S Gianella, V von Wyl, M Fischer, B Niederöst, M Battegay, E Bernasconi, M
Cavassini, A Rauch, B Hirschel, P Vernazza, R. Weber, B Joos, H Günthard.
Effect of Early Antiretroviral Therapy during primary HIV-1 infection on cellassociated HIV-1 DNA and Plasma HIV-1 RNA. Antiviral Therapy 2011;535-45.
R Kouyos, V von Wyl, S Yerly, J Böni, P Rieder, B Joos, P Taffé, C Shah, P
Bürgisser, T Klimkait, R Weber, B Hirschel, M Cavassini, A Rauch, M Battegay,
P Vernazza, E Bernasconi, M Rickenbach, B Ledergerber, S Bonhoeffer, H
Günthard. Ambiguous Nucleotide Calls From Population-based Sequencing
of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical
Infectious Diseases. 2011 15;532-9.
S Alizon, V von Wyl, T Stadler, R Kouyos, S Yerly, B Hirschel, J Böni, C Shah, T
Klimkait, H Furrer, A Rauch, P Vernazza, E Bernasconi, M Battegay M, P
11,665
0,986
2,878
0,684
6.245
0,957
3.161
0,741
9.154
0,986
6.41
0,971
11,665
0,986
11,675
1
9.154
0,986
4.092
0.867
3.161
0,741
9.154
0,986
9.127
0.97
25
26
27
28
29
30
31
32
33
34
35
36
37
Bürgisser, A Telenti, H Günthard, S Bonhoeffer S. Phylogenetic approach
reveals that virus genotype largely determines HIV set-point viral load. PLoS
Pathogens. 2010;6(9):e1001123.
J Rohrbach, N Robinson, G Harcourt, E Hammond, S Gaudieri, M Gorgievski,
A Telenti, O Keiser, H Günthard, B Hirschel, M Hoffmann E Bernasconi, M
Battegay, H Furrer, P Klenerman, A Rauch*. Cellular immune responses to
HCV core increase and HCV RNA levels decrease during successful
antiretroviral therapy. Gut 2010;59:1252-1258. *Corresponding author
A Nguyen, A Calmy, C Delhumeau. IK Mercier, M Cavassini, A Fayet-Mello, L
Elzi, D Genné D, A Rauch, E Bernasconi, B Hirschel. A randomized crossover
study to compare efavirenz and etravirine treatment. AIDS 2011, 25:57–63.
S Merani, D Petrovic, I James, A Chopra, D Cooper, E Freitas, A Rauch, J di
Iulio, D Cooper, M John, M Lucas, K Fitzmaurice, S McKiernan, S Norris, D
Kelleher, P Klenerman, S Gaudieri. Effect of immune pressure on Hepatitis C
virus evolution: insights from a single source outbreak. Hepatology;53:396405.
K Pfafferott, S Gaudieri, A Ulsenheimer, I James, M Heeg, D Nolan, M John, A
Rauch, S Mallal, A Lucas, P Klenerman, HM Diepolder, M Lucas. Constrained
pattern of viral evolution in acute and early HCV infection limits viral
plasticity. Plos One 2011;8:e16797.
Keiser O, Spycher B, Rauch A, Calmy A, Cavassini M, Glass TR, Nicca D,
Ledergerber B, Egger M. Outcomes of Antiretroviral Therapy in the Swiss HIV
Cohort Study: Latent Class Analysis. AIDS Behav. 2012 Feb;16(2):245-55.
Nguyen A, Calmy A, Delhumeau C, Mercier I, Cavassini M, Mello AF, Elzi L,
Rauch A, Bernasconi E, Schmid P, Hirschel B. A randomized cross-over study
to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011 Jul
31;25(12):1481-7.
J di Iulio J, A Ciuffi, K Fitzmaurice, D Kelleher, M Rotger, J Fellay, R Martinez,
S Pulit, H Furrer, HF Günthard, M Battegay, E Bernasconi, P Schmid, B
Hirschel, E Barnes, P Klenerman, A Telenti, A Rauch*. Estimating the net
contribution of interleukin-28B variation to spontaneous hepatitis C virus
clearance. Hepatology, 2011; 53 (5):1446-54.*corresponding author
*M Rotger, *J Dalmau, *A Rauch, *P McLaren, *S Bosinger, R Martinez, NG
Sandler, A Roque, J Liebner, M Battegay, E Bernasconi, P Descombes I
Erkizia, J Fellay, B Hirschel, M Miró, E Palou, M Hoffmann, M Massanella, J
Blanco, M Woods, HF Günthard, P de Bakker, DC Douek, G Silvestri, J
Martinez-Picado, A Telenti. Comparative transcriptomics of extreme
phenotypes of human HIV-1 infection and SIV infection in sooty mangabey
and rhesus macaque. J Clin Invest. 2011 May 9. *shared first authors
K. Mühlethaler, K Bögli, S Wasmer, C von Garnier, P Dumont, A Rauch, K
Mühlemann, C Garzoni. Quantitative PCR to diagnose pneumocystis
pneumonia in immunocompromised non-HIV patients. Eur Respir J. 2012;
39:971-8.
N Boillat, A Probst, V Da Costa, S Giulieri, E Bernasconi, A Calmy, L Elzi, A
Rauch, R Weber, B Bertisch, M Cavassini, PY Bochud. Impact of a Nurse
Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. J Acquir
Immune Defic Syndr. 2011 Dec 15;58(5):472-474.
Improved virological outcome in White patients infected with HIV-1 non-B
subtypes compared to subtype B. Scherrer AU, Ledergerber B, von Wyl V,
Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L,
Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study. Clin
Infect Dis. 2011 Dec;53(11):1143-52. Epub 2011 Oct 13.
von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M,
Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B,
Günthard HF; the Swiss HIV Cohort Study (SHCS).Early Antiretroviral Therapy
During Primary HIV-1 Infection Results in a Transient Reduction of the Viral
Setpoint upon Treatment Interruption. PLoS One. 2011;6(11):e27463. Epub
2011 Nov 15
M Stern, K Czaja, A Rauch, M Rickenbach, H F Günthard, M Battegay, J
Fellay, B Hirschel, C Hess and the Swiss HIV Cohort Study Group. HLA-Bw4
identifies a population of HIV-infected patients with an increased capacity to
10.111
0.973
6.245
0,957
11,665
0,986
4.092
0.867
3.949
0.973
6.245
0,957
11,665
0,986
13.079
0.972
5.895
0.958
4,425
0,857
9.154
0,986
4.092
0.867
3.00
0.614
38
39
40
41
42
43
44
control viral replication after structured treatment interruption. HIV
Medicine. 2012; Epub ahead of print.
S. Gaudieri, M. Lucas, A. Lucas, E. McKinnon, H. Albloushi, A. Rauch, J. di
Iulio, D. Di Martino, S. Prescott, MK. Tulic. Genetic variations in IL28B and
allergic diseases in children. PLOS One, 2012;7(1):e30607. Epub 2012 Jan 25
C Smit, JA Sterne, A. d’Aminio Monforte, M. Puoti, F. de Wolf, L. Peters, B.
Ledergerber, S. de Wit, H. Sambatakou, A. Rauch, F. Dabis on behalft of the
COHERE collaboration. Effect of Hepatitis C treatment on CD4 cell counts
and the risk of death in HIV-hepatitis C co-infected patients. Antiviral
Therapy, 2012; Epub ahead of print.
SK Pillai, MA bdel-Mohsen, J Guatelli, M Skasko, A Monto, K Fujimoto, S Yukl,
W Greene, A Rauch, J Fellay, M Battegay, B Hirschel, A Witteck, E
Bernasconi, B Ledergerber, H Günthard, J Wong, and the Swiss HIV Cohort
Study. Role of retroviral restriction factors in the interferon-γ-mediated
suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A. 2012 21;109(8):303540.
Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser
P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L,
Günthard HF; Swiss HIV Cohort Study. Improved virological outcome in
White patients infected with HIV-1 non-B subtypes compared to subtype B
Clin Infect Dis. 2011 Dec;53(11):1143-52.
R Simmons, C Sharp, C McClure, J Rohrbach, H Kovari, E Frangou, P
Simmonds, W Irving, A Rauch, P Bowness, P Klenerman, and the Swiss HIV
Cohort Study. Parvovirus 4 Infection and Clinical Outcome in High-Risk
Populations. J Infect Dis. 2012 Jun 15;205(12):1816-20.
Gasser O, Brander C, Wolbers M, Brown N, Rauch A, Günthard H, Battegay
M, Hess C; the Swiss HIV Cohort Study. Expansion of interferon-γ-secreting
HIV-specific T cells during successful antiretroviral therapy. HIV Med. 2012
Aug 30. Epub ahead of print.
Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle
M, Bernasconi E, Furrer H, Rauch A*; the Swiss HIV Cohort Study. Hepatitis C
Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic.
Clin Infect Dias. 2012. Aug 14. Epub ahead of print. .*corresponding author
4.092
0.867
3.161
0,741
9.681
9.154
0,986
6.41
0.971
3.00
0.614
9.154
0,986
B) Case Reports
1
2
3
4
A Rauch, M Egger, M Täuber. Unusual cause of diarrhea. Swiss Medical Forum.
2004;22:220-3.
Ch Hurni, A Rauch, N Trost, M Perrig, U Bürgi, AW Schoenenberger. Pulmonary
nodules and prednison therapy. Praxis 2008, 97:849-852.
A Rauch, S Droz, S Zimmerli, S Leib. Dysphagia in Elderly Women: Consider
Tetanus. Infection 2006; 34:35-8.
Wandeler G, Furrer H, Rauch A. Sustained virological response to a raltegravircontaining salvage therapy in an HIV-2-infected patient. AIDS. 2011 Nov
28;25(18):2306-8.
no IF
no IF
2.659
0.529
6.245
0,957
4.536
0,884
C) Reviews
1
2
3
4
A Martin, D Nolan, CA Almeida, A Rauch, S Mallal. Predicting and diagnosing
abacavir and nevirapine drug hypersensitivity: from bedside to bench and back
again. Pharmacogenomics 2006 7:15-23.
A. Lucas, S. Gaudieri, A. Rauch, D. Nolan. Cellular tropism of HIV-1 mediated and
constrained by coreceptro dependencies. 2005. J Viral Entry, 1, 17-27.
A Rauch, R Laird, E McKinnon, A Telenti, H Furrer, R Weber, D Smillie, S Gaudieri;
and the Swiss HIV Cohort Study. Influence of inhibitory KIRs and their HLA-C
ligands on resolving HCV infection. Tissue Antigens 2006;69 Suppl 1:237-40.
A Rauch*, S Gaudieri, C Thio, PY Bochud. Host Genetic Determinants of
Spontaneous Hepatitis C Clearance. Pharmacogenomics. 2009 Nov;10(11):181937. *corresponding author
No IF
2.588
0,705
4.536
0,884
5
6
7
A Rauch*, J Rohrbach, PY Bochud. The recent breakthroughs in the
understanding of host genomics in hepatitis C. Eur J Clin Invest. 2010
Oct;40(10):950-9. *corresponding author
A Rauch*, J Fellay. Personalized Hepatitis C Therapy: Opportunities and Pitfalls.
Expert Reviews of Molecular Diagnostics, 2011;127-9. *corresponding author
The European AIDS Treatment Network (NEAT) Acute Hepatitis C (AHC)
consensus panel: Acute hepatitis C in HIV-infected individuals –
recommendations from the NEAT consensus conference. AIDS 2011;25:399-409.
3.018
0.869
3,693
0.817
6.245
0,957